|
|
3줄모양
|
|
 |
NmydcqZaQQhtfxvruen |
 |
186 |
|
 |
| A Second Class stamp http://xxnxcom.site/sitemaps/1.html www cpm bolu youporns org sexye vidos The deal has more to do with financial planning than drug making, but that should hardly bother Elan’s shareholders. Investors will receive $6.25 a share in cash, about half as much again as is sitting on Elan’s balance sheet. True, some biotech aficionados may have little interest in shares in a consumer-drugs company. But, while Perrigo shares fell Monday, the stock would have to be overvalued by about 28% for the deal to fall shy of Royalty’s offer, notes Deutsche Bank. |
|
 |
Charlie |
 |
2020-04-25 21:28:02 |
|
|
|
|
|
|
|
|
|
